Why is gonorrhea becoming harder to treat?

The bacterium Neisseria gonorrhoeae is developing resistance to existing antibiotics, making infections increasingly difficult to cure.

What is the role of public-private partnerships in developing new antibiotics like zoliflodacin?

Public-private partnerships, like GARDP, are crucial for bringing new antibiotics to market when commercial incentives are low.

Home / Health / FDA Greenlights New Drugs for Superbug Gonorrhea

FDA Greenlights New Drugs for Superbug Gonorrhea

Q: What are the new FDA-approved drugs for gonorrhea?

The FDA has approved two new antibiotics, zoliflodacin and gepotidacin, for treating gonorrhea.

13 Dec

•

Summary

Two new antibiotics, zoliflodacin and gepotidacin, were approved by the FDA.
Gonorrhea has become increasingly resistant to existing antibiotic treatments.
The new drugs offer hope against a growing global threat of antimicrobial resistance.

FDA Greenlights New Drugs for Superbug Gonorrhea

The Food and Drug Administration has given the green light to two new antibiotics, zoliflodacin and gepotidacin, offering a significant advancement in the fight against gonorrhea. This sexually transmitted infection, caused by the bacterium Neisseria gonorrhoeae, has become notoriously resistant to many existing treatments, posing a growing global health challenge. The approval of these novel drugs marks a crucial victory in combating antimicrobial resistance.

Zoliflodacin received approval following a clinical trial demonstrating its safety and efficacy as a single oral dose. Gepotidacin, previously approved for urinary tract infections, also gained expanded use for gonorrhea. Infectious disease experts have expressed optimism, hailing the new treatments as a cause for celebration in the face of escalating antibiotic resistance, which complicates medical procedures and threatens public health.